Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Neuroprotection in Huntington;s Disease

Author(s): Raphael M. Bonelli, Anna K. Hodl and Hans-Peter Kapfhammer

Volume 2, Issue 2, 2005

Page: [143 - 147] Pages: 5

DOI: 10.2174/1570180053175133

Price: $65

Abstract

Minocycline, the 7-dimethylamino- 6-dimethyl-desoxytetracycline hydrochloride, is a caspase-1 inhibitor and may serve as anti-apoptotic agent, thereby acting neuroprotective. It directly inhibits both caspase-independent and -dependent mitochondrial cell death pathways, and decreases inducible nitric oxide synthetase activity. Minocycline delays disease progression in the transgenic mouse model of Huntington;s disease (HD), extending survival by 14%. HD is a late onset relentlessly progressive, neurodegenerative disorder with currently no cures or even effective therapies, death occurring 15 years after onset. In this review, recent clinical and preclinical data on minocycline in HD and neuroprotective alternatives discussed.

Keywords: neurodegenerative disorder, gliosis, highly unsaturated fatty acids, glutamate, nmda-receptor antagonist, gabaergic neurotransmission


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy